Oasmia Pharmaceutical

Stockholm: OASM

Market CapSEK971.2m

Last Close SEK2.17

Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar), docetaxel micellar and Cantrixil.

More Oasmia Pharmaceutical content >

Investment summary

Oasmia is focused on developing improved formulations of well-established cancer drugs through the application of its proprietary XR-17 platform. This solubility enhancing technology has received validation though a global partnership deal for lead asset Apealea (Cremophor-free paclitaxel) with Elevar Therapeutics across a variety of cancers. Apealea is approved in Europe for second-line ovarian cancer and Elevar is required to complete two additional studies before an NDA filing in the United States. Oasmia is working on additional nanoparticle formulations, including docetaxel micellar (Phase Ib prostate cancer) and the development of innovative drugs (preclinical stage). In-licensed asset Cantrixil is expected to start Phase II development in ovarian cancer in 2022. Oasmia’s animal health pipeline has two clinical stage assets, Paccal Vet and Doxophos Vet. At 30 June 2021, Oasmia had net cash of SEK176.3m, giving a cash runaway into FY23.

Y/E Dec
Revenue (SEKm)
EBITDA (SEKm)
PBT (SEKm)
EPS (öre)
P/E (x)
P/CF (x)
2019A 2.0 (119.2) (168.5) (68.5) N/A N/A
2020A 201.8 (10.1) (43.4) 0.2 1085.0 N/A
2021E 15.5 (135.1) (166.1) (32.5) N/A N/A
2022E 46.8 (106.5) (139.1) (26.5) N/A N/A
Industry outlook

Despite a slew of novel cancer drugs transforming care for many oncology indications, established chemotherapy regimens remain a cornerstone of treatment. Oasmia’s XR-17 technology is applicable to any solubility limited drug, which includes 10–15 different cytostatic agents, and can potentially provide an improved formulation and profile.

Last updated on 14/10/2021
Content on Oasmia Pharmaceutical
Oasmia Pharmaceutical – Focused on pillars of growth
Healthcare | Outlook | 7 October 2021
B56C9260-77A1-4FDB-AD0D-3D7F1C7781D7
Oasmia Pharmaceutical – Onwards and upwards
Healthcare | Update | 12 March 2021
B56C9260-77A1-4FDB-AD0D-3D7F1C7781D7
Oasmia Pharmaceutical – Clarity on pathway to US approval
Healthcare | Update | 17 December 2020
B56C9260-77A1-4FDB-AD0D-3D7F1C7781D7
View more
Register to receive research on Oasmia Pharmaceutical as it is published
Share price graph
Balance sheet
Forecast net cash (SEKm) 129.8
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (15.2) (28.3) (50.2)
Relative* (12.8) (27.3) (61.4)
52-week high/low SEK4.9/SEK2.2
*% relative to local index
Key management
Francois Martelet CEO
Fredrik Järrsten CFO